The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
George Au-Yeung
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
 
Andrew John Spillane
Honoraria - Lilly
Consulting or Advisory Role - QBiotics
 
Kerwin Frank Shannon
No Relationships to Disclose
 
David E. Gyorki
Honoraria - Amgen; BMSi; Novartis
Consulting or Advisory Role - Amgen; Bayer; QBiotics
Travel, Accommodations, Expenses - Amgen
 
Julie R. Howle
No Relationships to Disclose
 
Sydney Ch'ng
No Relationships to Disclose
 
Maria Gonzalez
No Relationships to Disclose
 
Robyn P.M. Saw
Honoraria - Merck Sharp & Dohme; Novartis; Qbiotics
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis; Qbiotics
Speakers' Bureau - Bristol-Myers Squibb/Sanofi; Novartis
 
Thomas Pennington
No Relationships to Disclose
 
Serigne N. Lo
No Relationships to Disclose
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Honoraria - GlaxoSmithKline; Harvard Medical School; Wake Forest School of Medicine
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; Merck Sharp & Dohme; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
(OPTIONAL) Uncompensated Relationships - Melanoma Institute Australia
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche